The present invention relates to a fusion protein resulting from the bonding of a cancer-specific antibody and a vasculogenesis suppressing agent, and relates to a composition for treating cancer comprising same. More specifically, in the present invention it is preferable that the cancer-specific antibody is trastuzumab or a fragment thereof, and the vasculogenesis suppressing agent is a VEGF-Trap. When the fusion protein according to the present invention is used, there are advantages in that vasculogenesis and cancer cell growth can be effectively suppressed even at lower doses than with trastuzumab or a VEGF-Trap, and side effects can also be minimised.La présente invention concerne une protéine de fusion constituée dun anticorps spécifique dun cancer lié à un agent supprimant la vasculogenèse. Linvention concerne également une composition destinée à traiter le cancer contenant la protéine de fusion. Plus précisément, lanticorps spécifique dun cancer est de préférence le trastuzumab ou un fragment de celui-ci, et lagent supprimant la vasculogenèse est de préférence un piège à VEGF. La protéine de fusion de linvention permet de supprimer efficacement la vasculogenèse et la croissance des cellules cancéreuses à des doses plus faibles que celles du trastuzumab ou dun piège à VEGF, tout en minimisant les effets secondaires.본 발명은 암 특이적 항체와 혈관신생 억제제가 결합된 융합 단백질 및 이를 포함하는 암 치료용 조성물에 관한 것으로, 구체적으로, 본 발명에 따른 바람직한 암 특이적 항체는 트라스투주맵 또는 이의 단편이며, 혈관신생 억제제는 VEGF-트랩이다. 본 발명에 따른 융합 단백질을 이용하면 트라스투주맵이나 VEGF-트랩에 비해낮은 용량으로도 효율적으로 혈관신생 및 암 세포의 증식을 억제할 수 있으며, 부작용도 최소화될 수 있다는 장점이 있다.
